Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michelle A Elliott

Showing results (71-80 of 90) with videos related to

Pageof 9
Sort By:
American Journal of Hematology|March 28, 2026
Thirty Years of Classical Hematology Drugs in the US: Approvals, Costs, and SalesLucas T Go, Lewis T Go, Michelle A Elliott, et al.
Leukemia & Lymphoma|November 30, 2012
A phase I/II trial of reduced intensity allogeneic hematopoietic cell transplant for hematologic malignancies using cladribine, thiotepa and rabbit antithymocyte globulinJeremy T Larsen, William J Hogan, Ivana N Micallef, et al.
British Journal of Haematology|March 5, 2020
Response to erythropoiesis-stimulating agents in patients with WHO-defined myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T)Guadalupe Antelo, Abhishek A Mangaonkar, Giacomo Coltro, et al.
American Journal of Hematology|June 15, 2022
A dynamic 3-factor survival model for acute myeloid leukemia that accounts for response to induction chemotherapyAyalew Tefferi, Naseema Gangat, Aref Al-Kali, et al.
European Journal of Haematology|January 29, 2008
Peripheral blood stem cell transplant for POEMS syndrome is associated with high rates of engraftment syndromeAngela Dispenzieri, Martha Q Lacy, Suzanne R Hayman, et al.
American Journal of Hematology|June 1, 2010
A Phase II study of (153)Sm-EDTMP and high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myelomaAngela Dispenzieri, Gregory A Wiseman, Martha Q Lacy, et al.
Blood Cancer Journal|March 13, 2023
Abnormal karyotype is an independent predictor of inferior survival in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)Mostafa Abdallah, Kristen McCullough, Rimal Ilyas, et al.
Mayo Clinic Proceedings|October 3, 2008
Autologous stem cell transplant in 716 patients with multiple myeloma: low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisciplinary quality initiativeMorie A Gertz, Stephen M Ansell, David Dingli, et al.
American Journal of Hematology|January 19, 2023
TP53 mutations and variant allele frequency in myelodysplastic syndromes with del(5q): A Mayo-Moffitt study of 156 informative casesFarah Fleti, Onyee Chan, Amritpal Singh, et al.
Blood Cancer Journal|August 11, 2023
Real-world experience with ponatinib therapy in chronic phase chronic myeloid leukemia: impact of depth of response on survival and prior exposure to nilotinib on arterial occlusive eventsMaymona G Abdelmagid, Aref Al-Kali, Mark R Litzow, et al.
Pageof 9

Showing results (71-80 of 90) with videos related to

Sort By:
Pageof 9
American Journal of Hematology|March 28, 2026
Thirty Years of Classical Hematology Drugs in the US: Approvals, Costs, and SalesLucas T Go, Lewis T Go, Michelle A Elliott, et al.
Leukemia & Lymphoma|November 30, 2012
A phase I/II trial of reduced intensity allogeneic hematopoietic cell transplant for hematologic malignancies using cladribine, thiotepa and rabbit antithymocyte globulinJeremy T Larsen, William J Hogan, Ivana N Micallef, et al.
British Journal of Haematology|March 5, 2020
Response to erythropoiesis-stimulating agents in patients with WHO-defined myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T)Guadalupe Antelo, Abhishek A Mangaonkar, Giacomo Coltro, et al.
American Journal of Hematology|June 15, 2022
A dynamic 3-factor survival model for acute myeloid leukemia that accounts for response to induction chemotherapyAyalew Tefferi, Naseema Gangat, Aref Al-Kali, et al.
European Journal of Haematology|January 29, 2008
Peripheral blood stem cell transplant for POEMS syndrome is associated with high rates of engraftment syndromeAngela Dispenzieri, Martha Q Lacy, Suzanne R Hayman, et al.
American Journal of Hematology|June 1, 2010
A Phase II study of (153)Sm-EDTMP and high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myelomaAngela Dispenzieri, Gregory A Wiseman, Martha Q Lacy, et al.
Blood Cancer Journal|March 13, 2023
Abnormal karyotype is an independent predictor of inferior survival in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)Mostafa Abdallah, Kristen McCullough, Rimal Ilyas, et al.
Mayo Clinic Proceedings|October 3, 2008
Autologous stem cell transplant in 716 patients with multiple myeloma: low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisciplinary quality initiativeMorie A Gertz, Stephen M Ansell, David Dingli, et al.
American Journal of Hematology|January 19, 2023
TP53 mutations and variant allele frequency in myelodysplastic syndromes with del(5q): A Mayo-Moffitt study of 156 informative casesFarah Fleti, Onyee Chan, Amritpal Singh, et al.
Blood Cancer Journal|August 11, 2023
Real-world experience with ponatinib therapy in chronic phase chronic myeloid leukemia: impact of depth of response on survival and prior exposure to nilotinib on arterial occlusive eventsMaymona G Abdelmagid, Aref Al-Kali, Mark R Litzow, et al.
Pageof 9